Company Overview and News
KUALA LUMPUR (Oct 16): The FBM KLCI is expected to start on a lacklustre note today, in line with the overnight fall at most global markets, as sentiment at the world bourses remains jittery with rising geopolitical tensions amid the simmering US-Sino trade conflict.
7181 6025 7121 0131
KUALA LUMPUR (Oct 15): Based on corporate announcements and news flow today, stocks in focus on Tuesday (Oct 16) may include Ideal United Bintang International Bhd, Hovid Bhd, Aturmaju Resources Bhd, KiP REIT, Berjaya Media Bhd, Xian Leng Holdings Bhd, Diversified Gateway Solutions Bhd and DBE Gurney Resources Bhd
7181 9687 6025 7121 0131
ALTHOUGH Star Media Group Bhd is currently not in its best financial state, the fact that it is still turning a profit sets it a cut above other struggling Bursa Malaysia-listed media companies. Many print-based media firms, not only those in Malaysia, are trying hard to stay afloat.
4502 5754 MIAHF 6025 MS
KUALA LUMPUR (Sept 25): The FBM KLCI is expected to drift lower today, tracking the overnight losses at most global markets as worries of a protracted trade spat between China and the United States (US) is likely to weigh on investor sentiment.
KUALA LUMPUR (Sept 24): Based on corporate announcements and news flow today, companies in focus tomorrow (Tuesday, Sept 25) may include: CIMB, Bina Puri, Heng Huat, Bintai Kinden, Mynews, MLabs, Yinson, Berjaya Media and Parkson Holdings.
PKSGF 7293 6025 3368 0175 CIMDF 5932 5657 1023 5347 PKSGY TNABY TNABF
KUALA LUMPUR (Sept 24): Berjaya Media Bhd, the publisher of The Sun newspaper, has reported a bigger loss in its latest quarterly financial results mainly due to a decrease in revenue.
6025 BSMAF 1818
KUALA LUMPUR (Aug 1): Berjaya Media Bhd (BMedia), which publishes The Sun newspaper, said it is still in the midst of formulating a plan to regularise its financial conditions.
6025 BSMAF 1818
2018-07-27 thestar.com.my - 1
2018-07-27 theedgemarkets - 1
KUALA LUMPUR(July 27): Berjaya Media Bhd (BMedia), which publishes The Sun Daily newspaper, has been granted an extension of time up to Dec 20, 2018 to submit a regularisation plan to the regulatory authorities.
In a filing with Bursa Malaysia, the group said that the lower losses were mainly because there was no further impairment loss on publishing rights incurred during the current quarter, as compared to a RM12mil impairment loss in the preceding period.
6025 BSMAF 1818
KUALA LUMPUR (June 26): Based on corporate announcements and news flow today, stocks in focus for Wednesday (June 27) may include the following: T7 Global Bhd, MSM Malaysia Holdings Bhd, Selangor Properties Bhd, APFT Bhd, Poh Huat, Alam Maritim Resources Bhd, Berjaya Media Bhd and Sunway Bhd.
1783 5115 SGPBY 6025 5202
KUALA LUMPUR (June 26): Berjaya Media Bhd (BMedia), which publishes the Sun newspaper, narrowed its net loss to RM6.03 million in the fourth financial quarter ended April 30, 2018 (4QFY18) from RM14.01 million a year ago, as it no longer has to incur impairment loss on publishing rights. In 4QFY17, the group incurred RM12 million in impairment loss.
6025 BSMAF 1818
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...